Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)

You may be eligible if

• Patients must have received all 3 drugs- an anthracycline, taxane, and capecitabine (alone or in combination) and be resistant
• No more than 3 prior chemotherapy regimens in the metastatic setting
• Must have at least one target lesion that is radiographically measurable
• Good performance status
• No history of or current brain or leptomeningeal disease